Drug information provided by: Merative, Micromedex®
Flotufolastat F 18 injection is used with a PET scan (positron emission tomography) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. It is given in patients with suspected metastasis (cancer that has spread to the other parts of the body) who are candidates for initial treatment and with suspected recurrence (cancer that keeps coming back) based on an increased serum prostate-specific antigen (PSA) level.
Flotufolastat F 18 is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents, which may be used to find and treat certain diseases or to study the function of the body's organs.
This medicine is to be given only by or under the direct supervision of a doctor with specialized training in nuclear medicine.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.